WCG by the numbers. Our connectivity, solutions, data intelligence, and expertise support your success.

Your go-to hub for industry-leading practices, guidelines, metrics, templates, purpose-built tools, research, and webinars—exclusively for WCG Avoca Quality Consortium members.

Successfully implement ICH E6 (R3) guidance updates with support through WCG’s Avoca Quality Consortium (AQC) membership and consulting solutions. Leverage the AQC’s ICH E6 (R2)/(R3) Side-by-Side Comparison resource to support continuous quality compliance.

PHILADELPHIA, PA – March 10, 2025 – Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research.

Drawing from WCG’s deep expertise, this year’s report focuses on five pivotal areas, offering actionable insights to navigate the future of clinical trials. Diversity in Clinical Trials remains a cornerstone of equitable research.

Over 55 years’ experience across all trial phases and therapeutic areas makes WCG the gold-standard for ethical, scientific, and regulatory review. Get the answers and insights you need with the industry’s largest network of vetted sites and accredited committee experts.

Drive better study timelines and outcomes from the start with WCG's specialized study planning solutions.

There’s no time for doubt or delays. WCG’s clinical endpoint solutions demystify trial efficacy by reducing clinical trial error rate and, subsequently, the risk of inconclusive and unsalvageable studies.

WCG’s full-service medical imaging core lab provides comprehensive clinical trial imaging services to pharmaceutical, biotechnology, and medical device companies across all therapeutic areas. Navigate the complexities of clinical trials with …

WCG Site Feasibility helps you rapidly identify sites specifically qualified for your study, because we recruit using sites’ historical performance—enrollment, experience and results—in clinical trials. It adds up to significantly faster site selection, study activation and time to market.